Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

terested parties may participate in the webcast which can be accessed at www.bdsi.com.  For those unable to access the webcast, the audio portion of the call can be accessed toll-free at (866) 516-3002 or at (760) 298-5082.  For those who are not able to listen to the live broadcast, a replay of the call will be made available on the website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 The UPMC Center for Health Security ... the Emerging Leaders in Biosecurity Initiative (ELBI). As part ... field of biosecurity, UPMC has selected 28 US and ... of backgrounds, including biological science, medicine, policy, the military, ... "With the vision and support of the Defense Threat ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... N.Y., Sept. 24 BioSpecifics,Technologies Corp. (OTC ... in class collagenase based products, today announced ... Board of Directors, increasing,the Board to 7 ... experience with biotechnology companies as he has ...
... Biosciences announces,an enhanced matching funds program to ... in matching funds is available with,LI-COR providing ... institution. The,Genomics Education Matching Funds (GEMF) program ... colleges acquire LI-COR DNA sequencing systems,for use ...
... immune enhancement during cold & flu season, PURCHASE, ... Reviews (Vol. 66(9):526-531) by Dr. Barry W. Ritz, PhD,Department ... AHCC impacts the immune response against a number of ... in vivo studies evaluating,the effect of AHCC supplementation on ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors 2Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents 2
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... from the University of Guelph, published Tuesday in the ... industrial extraction in a northern Ontario old-growth red pine ... would significantly threaten biodiversity in Canada. The study ... irreplaceable system." "Wolf Lake Forest deserves intensive study, ...
... the old. Until now, scientists have never agreed on exactly ... Sheffield may provide the answer. Engineers and biologists ... theory-- that skin has ,sleeping, stem cells which can be ... regrows. The research-- conducted in collaboration with The Procter & ...
... understanding of thermodynamics is fundamentally incorrect if applied to ... new research from University College London (UCL) and the ... the rapidly emerging field of quantum thermodynamics. The ... wide applications in small systems, from nanoscale engines and ...
Cached Biology News:New research: Wolf Lake ancient forest is endangered ecosystem 2New research: Wolf Lake ancient forest is endangered ecosystem 3Virtual skin model reveals secrets of skin aging 2Virtual skin model reveals secrets of skin aging 3Quantum engines must break down 2
... Source: Pseudomonas atlantica Description: Beta-Agarase ... RNA fragments from low-melting-temperature agarose. Beta-Agarase ... disaccharides. Tested User Friendly Properties: Heat ... 30,000 Da Optimum pH: 6.5 Purity: ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
iEMS Thermal Microplate Holder...
...
Biology Products: